摘要胰腺癌新辅助治疗作为胰腺癌治疗的新方向，已被证实可改善患者预后。新辅助治疗在多学科诊治(MDT)模式下，集合多学科优势，解决患者在诊断和治疗中的难题，提供精准全面且个体化的诊疗措施，使患者临床受益最大化。本文总结现阶段胰腺癌新辅助治疗在患者选择、治疗方案选择、疗效评价和手术选择中仍存在的问题，探索MDT模式下开展临床研究和胰腺癌新辅助治疗的方向。

abstractsAs a new direction of pancreatic cancer treatment, neoadjuvant therapy for pancreatic cancer has been confirmed to be able to improve the prognosis of the patients. Under multidisciplinary treatment (MDT) mode, neoadjuvant therapy combines multidisciplinary advantages to solve patients′ problems of diagnosis and treatment, provides accurate, comprehensive and individual treatments, and maximizes the clinical benefit for patients. In this article, we summarize the present problems of neoadjuvant therapy for pancreatic cancer in patient selection, treatment regimen selection, treatment response evaluation and surgical selection, and explore the direction of clinical research and neoadjuvant therapy for pancreatic cancer under MDT mode.